AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05511831 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: standard treatment
Description: Standard treatment methods will be determined according to the Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2019) \[19\], including primary PCI, dual antiplatelet, anticoagulation, ACEI/ARB/ARNI, β-receptor blockade drugs, statins, etc.
Study NCT06326502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETN101
Description: Oral administration
Study NCT05636566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: inhalational anaesthesia for maintenance
Study NCT05636566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol infusion for maintance
Description: propofol infusion after induction for maintenance of anaesthesia
Study NCT05636566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia
Study NCT04731402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure, laughter yoga and mindfulness stress reduction program
Description: Initiatives will be applied to the experimental group. only measurement tools will be applied to the control group
Study NCT06551220 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab Deruxtecan
Description: The patients received Trastuzumab Deruxtecan at a dose of 5.4 mg/kg every 3 weeks until disease progression or unacceptable adverse effects occurred.
Study NCT05544253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mitomycin C-based hyperthermic intraperitoneal chemotherapy
Description: The patients with srHCC or PM of HCC were randomly allocated to either the HIPEC group or the control group. All of them have received open liver resection and perfusion tubes had been set in the operation. For patients with PM of HCC served operation, we are subject to reach CC score at 0-1 to creating sufficient conditions for HIPEC. Finally, place the HIPEC tubes. Implementation of HIPEC was administered 3times on the 1st, 3rd, 5th days within one week after operation. We used intraperitoneal hyperthermic perfusion device (BR-TRG-IITM, Bao Rui medical corporation, Guangdong, China) to achieve HIPEC. The abdominal temperature was maintained at 43°C (109°F) by circulating heated saline. The perfusion volume was 3000ml of normal saline, and the chemotherapeutic agent of mitomycin C was 10mg for a 1-hour perfusion period.
Study NCT04868292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR206
Description: Three 100 mg SPR206 intravenous doses administered every 8 hours
Study NCT06504836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait training with biofeedback
Description: Gait training include treadmill and overground walking. The biofeedback device system will provide real-time feedback on hip extension angles.
Study NCT06504836 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait training without biofeedback
Description: Gait training include treadmill and overground walking.
Study NCT05319626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compression socks
Description: The compression socks have a clinical pressure of 23-30 mm Hg. The socks are dressed to the participants based on the manufacturer's sizing guidelines.
Study NCT05319626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: textured insoles
Description: The textured insoles have small, pyramidal peaks with centre-to-centre distances of approximately 2.5 mm (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
Study NCT05319626 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: smooth socks
Description: The smooth socks are a commercial stocking that does not have a compression feature, but has a similar thickness and color to the compression stocking. They have standard size.
Study NCT05319626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smooth socks
Description: The smooth socks are a commercial stocking that does not have a compression feature, but has a similar thickness and color to the compression stocking. They have standard size.
Study NCT05319626 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: smooth insoles
Description: The smooth insoles have a completely flat surface (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
Study NCT05319626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smooth insoles
Description: The smooth insoles have a completely flat surface (Evalite Pyramid EVA, 3 mm thickness, shore value A50, black). The insoles cut to a range of men's and women's standard EU shoe sizes. During the testing process, they are worn within a standardised shoe.
Study NCT04865250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg abs day 1 q22 (iv)
Description: Immune checkpoint blockade antibody ATEZOLIZUMAB directed against PD-L1 (Programmed death-ligand 1); Carboplatin; Nab-Paclitaxel (iv)
Study NCT05811767 — intervention group
Intervention type: OTHER
Intervention: Health Examination
Description: The study is a cross-sectional study and therefore there is no intervention. The study consist only of tests, questionnaires and a blood test. See the elements under outcomes measures.
Study NCT05543460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MARPE with Corticopunctures
Description: Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) used to correct the maxillary transverse deficiency aided with corticopunctures made along the mid-palatal suture
Study NCT05543460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MARPE
Description: Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) used to correct the maxillary transverse deficiency
Study NCT05222737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: medency diode laser
Description: intra pocket application of diode laser
Study NCT05222737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spirazole forte
Description: adminstration of spirazole forte with a dose 17 mg per kg
Study NCT04790604 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community Health Navigator Program
Description: Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
Study NCT04790604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Navigator Program
Description: Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
Study NCT05611840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Description: one-stage robotic common bile duct exploration and cholecystectomy
Study NCT05611840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endo-laparoscopic surgery
Description: Two-stage therapeutic ERCP plus interval laparoscopic cholecystectomy
Study NCT04831515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A
Description: daily disposable soft contact lens - test lens
Study NCT04831515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens A
Description: daily disposable soft contact lens - test lens
Study NCT04831515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B
Description: daily disposable soft contact lens - control lens
Study NCT04831515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens B
Description: daily disposable soft contact lens - control lens
Study NCT05559281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botulinum
Description: injection of Botulinum Toxin injection in lip muscles following cleft lip repair surgically.
Study NCT05559281 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fisher technique
Description: The cleft lip will be treated surgically using the Fisher technique only.
Study NCT06112899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Hamstring Exercise
Description: The NHE, also referred to as the nordic curl, is designed to improve eccentric strength of the hamstring muscles. Individuals start in a kneeling position, with the torso from the knees upward held rigid and straight. The training partner ensures that the individual's feet are in contact with the ground throughout the exercise by applying pressure to the player's heels/lower legs. The individual then lowers his upper body to the ground, as slowly as possible to maximize loading in the eccentric phase. Hands and arms are used to break his forward fall and to push him back up after the chest has touched the ground, to minimize loading in the concentric phase.The exercise protocol is planned as 5 sets of 8 repetitions and 2 minutes of rest between each set.
Study NCT05251649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS combined with 40 Hz sound stimulation
Description: The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).~Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). Sound stimulation was turned on simultaneously at the beginning of tACS. The duration of sound stimulation was set to 5 min stimulation, 5 min rest, 5 min stimulation, 1 min rest, and continued stimulation until the end of electrical stimulation while sound stimulation was turned off.
Study NCT05766852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Somatic Psychoeducational Intervention
Description: Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
Study NCT05766852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Somatic Psychoeducational Intervention
Description: Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
Study NCT05666609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: placement of non-cutting seton (silicone)
Description: Treatment of Fistula in ano is conducted according to the institution's treatment guidelines. Silicon seton placement is conducted under general anesthesia. Identification of the FIA is secured by the insertion of a bulb-headed lacrimal probe, on which a silicon vessel loop is attached and pulled through the entire fistulous tract. In case of a perianal abscess, drainage and sphincter-sparing debridement is performed followed by secondary wound healing. The loop is ligated loosely outside the anus without any additional tension to the skin. Duration of placed seton is depending on group assignment and is set to either 4 or 12 weeks.
Study NCT06199154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Participants will receive with 25 mcg or 50 mcg vaginal misoprostol every 4 hours.
Study NCT06199154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Participants will receive with 25 mcg or 50 mcg vaginal misoprostol every 4 hours.
Study NCT06558513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004 tablets
Description: XNW5004 an EZH2 inhibitor, BID, administered in continuous
Study NCT05672888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: 100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with best available treatment.
Study NCT05672888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (given as two placebo tablets) administered orally BID with best available treatment.
Study NCT05128682 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urodynamic testing with and without pudendal nerve stimulation
Description: A urodynamic test (UDT) for eligible subjects with and without acute PNS will be conducted. Prior to introducing the acute PNS, the subject's original stimulation properties will be turned off. The implanted neurostimulator device will be programmed to deliver acute PNS per individual tolerance level with the objective of increasing external urethral sphincter pressure. The LPP during Valsalva maneuver or forceful coughing will be assessed with and without acute PNS. The LPP will be assessed at increasing bladder volumes until major detrusor instability, significant leakage (more than drops, stream) or subject discomfort (strong desire to void) is observed. Finally, a UPP with PNS set in an on/off cycling regimen will be conducted to observe the effect on pressures along the length of the urethra.
Study NCT06165666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Approach by functional objectives
Description: The therapeutic approach that will be administered to the EG will be based on the training of specific tasks aimed at functional objectives. Each session will begin with activities to activate the muscles of the trunk, pelvis and lower limbs, to modify atypical movement patterns and prepare the muscles for a more effective contraction. Subsequently, activity training will be carried out in a functional and meaningful context, aimed at specific and significant functional objectives for the participant and previously agreed upon with them.
Study NCT06165666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment protocol
Description: The therapeutic approach of the participants assigned to the CG will be aimed at maintaining joint ranges and transfer work, passive mobilization of the paretic lower and upper limb, maintenance of sitting posture with/without assistance, transfer from sitting to standing, from standing to sitting. and coordination work. Subsequently, initiation of walking with a support product and/or help, if possible.
Study NCT05251649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation
Description: The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).
Study NCT05251649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 40 Hz sound stimulation
Description: Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). The duration of the sound stimulation was set to stimulate for 5 min, rest for 5 min, stimulate for 5 min, rest for 1 min, and last for a total of 20 min. 15 sessions of 20 min were performed over a period of 3 weeks (21 days).
Study NCT05738330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Monitoring on Renal Replacement Therapy - Hemodialysis (SMaRRT-HD)
Description: Dialysis clinics randomized to the SMaRRT-HD group will use the SMaRRT-HD system to capture patient-reported symptoms and support clinician follow-up. The online system includes the patient symptom ePROM surveys, clinician real-time email alerts, clinician guidances for symptom management, and patient-facing symptom reports as well as an administrative dashboard supporting management of trial participants at clinics using SMaRRT-HD. Designated clinic personnel (i.e., patient care technicians and nurses) will receive training on how to use the system to administer the symptom ePROM surveys to patients on tablet computers. Designated clinic nurses and medical providers will receive training on how to access guidances for symptom management and patient-facing symptom reports in the SMaRRT-HD system. For trial participants in SMaRRT-HD clinics, the SMaRRT-HD system will be implemented in addition to the Usual Care approach to symptom monitoring.
Study NCT05738330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Dialysis clinics randomized to Usual Care will not adopt SMaRRT-HD or any other trial-driven procedures. Usual Care clinics will monitor symptoms through clinical care interactions with participants and by administering a CMS-mandated Health-Related Quality of Life (HRQOL) survey that includes questions about symptoms.
Study NCT04778592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX-018810
Description: Study Drug
Study NCT04778592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06447909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment App
Description: The behavioral treatment app content consists of tasks that caregivers can assign to their children in the app (e.g., finish homework, make bed, etc.). These tasks are completed offline, and then caregivers approve the child's completion of those tasks through the app, administering a token reward (coins) in-app. In the child version of the app, children take care of a virtual pet by feeding, cleaning, buying various accessories (using in-game coins), and exploring different lands with the virtual pet. The caregiver-assigned token coins can be used to redeem items needed to raise their pet, and access virtual lands. Caregivers can also choose to have their child redeem virtual tokens for real-life rewards. Ultimately, the app combines a video game with evidence-based principles to help children practice important tasks and behaviors as administered by caregivers.
Study NCT06447909 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham app
Description: As described above, the child will access a virtual pet that they can feed, clean and buy various accessories by redeeming virtual coins. They will not be able to explore different lands with that pet. Coins in the placebo version will be rewarded non-contingently. Additionally, children will not be able to redeem coins for real-life rewards as above in the treatment app. Caregivers will not need to review and approve tasks in order to redeem coins. The caregiver-version of the app will not contain the Assigned or Review tabs as assigned above, since the child will earn coins regardless of whether or not they complete tasks, so caregivers will not be able to review nor assign tasks. Instead, caregivers in this group will only have access to the guide tab which will contain helpful articles the parent can read about disruptive behavior problems in children.
Study NCT04694781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN6051
Description: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
Study NCT04694781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
Study NCT04313465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate discharge
Description: Participants discharged after initial blood test for cardiac troponin and risk stratification using the T-MACS decision aid
Study NCT04477616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 7 regimen
Description: patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC >= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
Study NCT04477616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Day 3 regimen
Description: patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC >= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
Study NCT05020574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Given orally (PO)